Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX ) 5.190 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amylyx Pharmaceuticals, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November November 18, 2024 Via Benzinga Exposures Fossil Fuels Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday November 18, 2024 Via Benzinga This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday November 18, 2024 Via Benzinga Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results November 07, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Analyst Ratings For Amylyx Pharma July 12, 2024 Via Benzinga 6 Analysts Assess Amylyx Pharma: What You Need To Know June 24, 2024 Via Benzinga Breaking Down Amylyx Pharma: 9 Analysts Share Their Views May 10, 2024 Via Benzinga Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 November 04, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Why Amylyx Pharmaceuticals Stock Was So Healthy This Week October 18, 2024 The company seems to have a winner on its hands with a drug that targets a rare genetic disorder. Via The Motley Fool Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome October 17, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 October 15, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying September 17, 2024 Via Benzinga Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences August 28, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration August 12, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results August 08, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 August 05, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome August 02, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday July 12, 2024 Via Benzinga Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? July 10, 2024 Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and... Via Benzinga Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation July 10, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide July 09, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results May 09, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference May 08, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder April 10, 2024 Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, visual decline, and overall disease burden. Safety profile consistent. Via Benzinga Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome April 10, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 08, 2024 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 08, 2024 WHY: NEW YORK, NY - (NewMediaWire) - April 08, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November... Via TheNewswire.com Topics Lawsuit Exposures Financial Legal < Previous 1 2 3 4 5 6 7 8 9 ... 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
